Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9H2X9
UPID:
S12A5_HUMAN
Alternative names:
Electroneutral potassium-chloride cotransporter 2; K-Cl cotransporter 2; Neuronal K-Cl cotransporter
Alternative UPACC:
Q9H2X9; A2RTX2; Q5VZ41; Q9H4Z0; Q9ULP4
Background:
Solute carrier family 12 member 5, also known as the electroneutral potassium-chloride cotransporter 2 (K-Cl cotransporter 2), plays a pivotal role in neuronal Cl(-) homeostasis. It mediates potassium-chloride cotransport in mature neurons, essential for maintaining low neuronal Cl(-) levels. This function is crucial for the hyperpolarization and inhibition of neurons following GABA-A and glycine receptor activation. Additionally, it contributes to dendritic spine formation and maturation, highlighting its significance in neural architecture and function.
Therapeutic significance:
The protein is implicated in severe neurological disorders, including Developmental and epileptic encephalopathy 34 and Epilepsy, idiopathic generalized 14. These conditions are characterized by refractory seizures and cognitive impairments, linked to mutations affecting the gene encoding this cotransporter. Understanding its role could lead to novel therapeutic strategies targeting these debilitating epilepsies, offering hope for improved treatments and outcomes.